PDF(Pubmed)
Abstract：
BACKGROUND: The leishmaniases are among the group of neglected tropical diseases that cause significant morbidity and mortality each year. Currently, the East Africa region has the highest visceral leishmaniasis burden in the world. Ethiopia is one of the East African countries that reports both visceral and cutaneous forms of the disease. As part of the Nairobi Declaration, Ethiopia showed commitment to the elimination of visceral leishmaniasis by 2030. In this endeavour, it is important to understand the scope of research conducted on leishmaniases in the country and identify where the research gaps exist. Determining the research landscape is vital in the plan towards leishmaniases control and elimination. It will help to reference conducted research, determine if systematic reviews are warranted and help prioritise future research directions.
METHODS: This protocol was developed with reference to the JBI Scoping Review Methodology Group\'s guidance on conducting scoping reviews and the PRISMA-ScR reporting guidelines for scoping reviews. The following databases will be searched: PubMed, Embase via Embase.com, Web of Science Core Collection, Cochrane CENTRAL, Global Index Medicus, ClinicalTrials.gov, the Pan African Clinical Trials Registry and PROSPERO. Locally published literature that may not be indexed in the above-mentioned systems will be identified through team members familiar with the setting. Each record will be dually and blindly reviewed in an abstract-title screen and full-text screen using inclusion-exclusion criteria. Included articles must contain an in-depth discussion of leishmaniasis in Ethiopia. Data extracted will consist of study themes, study types, and categories and subcategories each defined in the developed codebook, in addition to type of leishmania, year of publication, funding source and the number of citations. Results will be reported with summary statistics.
BACKGROUND: Individual consenting and ethical approvals are not applicable. We plan to disseminate our findings to the appropriate stakeholders.
METHODS: This protocol was developed with reference to the JBI Scoping Review Methodology Group\'s guidance on conducting scoping reviews and the PRISMA-ScR reporting guidelines for scoping reviews. The following databases will be searched: PubMed, Embase via Embase.com, Web of Science Core Collection, Cochrane CENTRAL, Global Index Medicus, ClinicalTrials.gov, the Pan African Clinical Trials Registry and PROSPERO. Locally published literature that may not be indexed in the above-mentioned systems will be identified through team members familiar with the setting. Each record will be dually and blindly reviewed in an abstract-title screen and full-text screen using inclusion-exclusion criteria. Included articles must contain an in-depth discussion of leishmaniasis in Ethiopia. Data extracted will consist of study themes, study types, and categories and subcategories each defined in the developed codebook, in addition to type of leishmania, year of publication, funding source and the number of citations. Results will be reported with summary statistics.
BACKGROUND: Individual consenting and ethical approvals are not applicable. We plan to disseminate our findings to the appropriate stakeholders.
摘要：
背景：利什曼尼酶是被忽视的热带病之一，每年引起大量发病率和死亡率。目前,东非地区是世界上内脏利什曼病负担最高的地区。埃塞俄比亚是报告该疾病的内脏和皮肤形式的东非国家之一。作为《内罗毕宣言》的一部分，埃塞俄比亚承诺到2030年消除内脏利什曼病。在这一努力中,重要的是要了解该国对利什曼虫进行的研究范围，并确定存在研究空白的地方。确定研究环境在控制和消除利什曼虫的计划中至关重要。这将有助于参考进行的研究，确定是否有必要进行系统评价，并帮助确定未来的研究方向。
方法：本方案是参考JBI范围审查方法学组关于开展范围审查的指南和范围审查的PRISMA-ScR报告指南制定的。将搜索以下数据库:PubMed,Embase通过Embase.com，WebofScience核心合集,科克伦中部,全球指数Medicus，ClinicalTrials.gov,泛非临床试验注册和PROSPERO。可能未在上述系统中索引的本地出版文献将通过熟悉设置的团队成员进行识别。每个记录将使用包含排除标准在摘要标题屏幕和全文屏幕中进行双重和盲目审查。纳入的文章必须包含对埃塞俄比亚利什曼病的深入讨论。提取的数据将包括研究主题，研究类型,以及在开发的码本中定义的类别和子类别，除了利什曼原虫的类型,出版年份,资金来源和引用次数。结果将通过汇总统计来报告。
背景：个人同意和道德批准不适用。我们计划将我们的研究结果传播给适当的利益相关者。
方法：本方案是参考JBI范围审查方法学组关于开展范围审查的指南和范围审查的PRISMA-ScR报告指南制定的。将搜索以下数据库:PubMed,Embase通过Embase.com，WebofScience核心合集,科克伦中部,全球指数Medicus，ClinicalTrials.gov,泛非临床试验注册和PROSPERO。可能未在上述系统中索引的本地出版文献将通过熟悉设置的团队成员进行识别。每个记录将使用包含排除标准在摘要标题屏幕和全文屏幕中进行双重和盲目审查。纳入的文章必须包含对埃塞俄比亚利什曼病的深入讨论。提取的数据将包括研究主题，研究类型,以及在开发的码本中定义的类别和子类别，除了利什曼原虫的类型,出版年份,资金来源和引用次数。结果将通过汇总统计来报告。
背景：个人同意和道德批准不适用。我们计划将我们的研究结果传播给适当的利益相关者。
